SparingVision

À propos

SparingVision is a biotechnology company focused on the discovering and development of saving vision treatments in inherited retinal diseases. SparingVision has been created on strong expertise and technology from Institut de la Vision in Paris. SparingVision'? therapeutic approach is to prevent and slow down progression of cones degeneration, first step in retinitis pigmentosa evolution, leading to total death of all the photoreceptors and blindness. The innovative approach is therefore independent of causal mutation and applies to advanced stages of the condition. SparingVision’ lead product candidate, begins preclinical trial. SparingVision is supported by Foundation Fighting Blindness, a non-profit research center based in USA, as well as an international Scientific Advisory Board.